Laurus is getting into niche fields. They have taken 34% stake in ImmunoACT, an offspring of Bombay IIT, which is into CAR-T cell treatment for leukemia and lymphoma cancers. Their treatment is already approved in India by Central Drugs Standard Control Organization. ImmunoACT can treat maximum of 500 patients now which will be increased to 3000 patients by 2025. The cost for one cancer patient is about Rs 30-40 lakhs, which is only 10% of the cost in the US. ImmunoACT also signed MoU with Mexican health ministry to start clinical trails for CAR-T from this year. Hugh potential if their CAR-T treatment is approved in Mexico too. Cancer is the third largest cause of deaths in Mexico and large number of people travels from the US to Mexico for treatment. ImmunoACT will be able to capture other markets such as Latin America, Africa, Europe and Asia also.
https://www.ipn.mx/english/press-releases/view-press-release.html?y=2022&n=159&t=17
CAR-T technology can also be used for treatment of HIV, breast cancer and other solid cancers. Hence, the target market is huge.
Apart from ImmunoACT, Laurus has signed an agreement with IIT Kanpur for Cell and gene therapy. Laurus is building a lab for IIT researchers to carry out their research and Laurus will be commercialising the products once IIT Kanpur gets approvals from the authority. Huge potential.
Their investment into Laurus Bio is also good. They are into developing enzymes which are animal free recombinant proteins. Basically developing plant based proteins for medicines and food. I believe this is also good investment.
Disclaimer: I am invested in Laurus. My view may be biased.
| Subscribe To Our Free Newsletter |
